Adamas to Host Investor and Analyst Meeting on September 18, 2017
September 13 2017 - 4:54PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it
will host an Investor and Analyst meeting on Monday, September 18,
2017 from 8:00 a.m. – 11:00 a.m. ET in New York, NY. The event will
be hosted by members of the Adamas executive management team and
will feature presentations from Key Opinion Leaders in the fields
of Parkinson’s disease and Multiple sclerosis.
The event will provide an overview of the market
opportunity and commercial plans for GOCOVRI™ (amantadine) extended
release capsules, recently approved by the U.S. Food and Drug
Administration (FDA) for the treatment of dyskinesia in patients
with Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications. In addition, the
company will provide an overview of its clinical development
programs: ADS-5102, a product candidate for the treatment of
multiple sclerosis walking impairment and ADS-4101, a product
candidate for the treatment of partial onset seizures in patients
with epilepsy.
Attendance at this event is by invitation only.
For additional event details, please contact Marcy Nanus at
mnanus@troutgroup.com. A live webcast of the event can be accessed
on the Investors section of the Adamas website at
http://ir.adamaspharma.com/events.cfm and will be available for
replay until October 18, 2017.
About GOCOVRIGOCOVRI is the
first and only medicine approved by the FDA for the treatment of
dyskinesia in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without concomitant dopaminergic
medications. For more information about GOCOVRI, including
Important Safety Information, please see the full Prescribing
Information available at www.GOCOVRI.com.
About Adamas Pharmaceuticals,
Inc.At Adamas, we believe in the power and the promise of
medicines derived from a deep understanding of time-dependent
biology. Our expertise lies in uncovering and mapping the
relationship between disease and drug activity. From there, we
strive to create medicines with therapeutic profiles that match the
pattern of disease to drive a more significant and durable clinical
effect. This understanding of time-dependent biological processes
informs our every innovation, targeting advancement in treatment of
chronic neurologic disorders. Our portfolio includes:
GOCOVRI™ (amantadine) extended release capsules (previously
ADS-5102), the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications; ADS-5102 in development for the treatment
of multiple sclerosis walking impairment and additional indications
in Parkinson’s disease, and ADS-4101, a high-dose, modified-release
lacosamide in Phase 1 clinical development for the treatment of
partial onset seizures in patients with epilepsy. Additionally,
Adamas licensed assets are currently marketed by Allergan under the
brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to
receive royalties on sales of these medicines beginning in June
2018 and May 2020, respectively. For more information, please visit
www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz
Pharma GmbH & Co. KGaA.
Forward-looking Statements
Statements contained in this press release regarding expected
future events are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
but not limited to, statements contained in this press release
regarding the expected benefits of GOCOVRI, physician and
patient access in fourth quarter 2017 and launch of GOCOVRI
(amantadine) extended release capsules (previously ADS-5102) in
January 2018 for the treatment of dyskinesia in patients with
Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications, and Adamas’ plans to
offer a number of programs providing patient access support
throughout the course of treatment, along with commercial copay
assistance and financial assistance for patients who are uninsured
or underinsured. Words such as “potentially,” “expected,”
“will,” “plans” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. For a description of
risks and uncertainties that could cause actual results to differ
from those expressed in forward-looking statements, including risks
relating to Adamas’ research, clinical, development, and commercial
activities relating to ADS-5102 and ADS-4101, and the regulatory
and competitive environment and Adamas’ business in general, see
Adamas’ Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 8, 2017. Investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this release. Adamas undertakes no
obligation to update any forward-looking statement in this press
release.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Oct 2023 to Oct 2024